尽管Legend Biotech在癌症CAR-T疗法中具有强劲增长潜力，Truist仍将其评级降至“持有”。 Truist downgraded Legend Biotech to "hold" despite strong growth potential in its cancer CAR-T therapies.

传奇生物技术 (LEGN) 的评级由特鲁斯特金融公司从"强购"降低到"持有",尽管该股票保持了共识"中等购买"评级和平均价格目标为55.08美元. Legend Biotech (LEGN) was downgraded from "strong-buy" to "hold" by Truist Financial, though the stock maintains a consensus "moderate buy" rating and an average price target of $55.08. 该公司总部设在新泽西州萨默塞特,在上海研发,开发CAR-T癌症疗法,由经批准的多种近视瘤卡维克蒂药物牵头,并得到Janssen Biotech和Novartis伙伴关系的支持。 The company, based in Somerset, New Jersey, with R&D in Shanghai, develops CAR-T therapies for cancer, led by its approved drug Carvykti for multiple myeloma, supported by partnerships with Janssen Biotech and Novartis. 尽管目前股价约为19美元,市场上限为36.5亿美元,流动性强,但传奇生物科技仍然无利可图,负P/E为30.38,负EPS为-1.18。 Despite a current stock price around $19, a market cap of $3.65 billion, and strong liquidity, Legend Biotech remains unprofitable with a negative P/E of -30.38 and a negative EPS of -1.28. 根据63.07美元的目标,分析家预测了显著的反向收益,潜在收益为248%,但由于生物技术部门的发展不确定性,风险依然存在。 Analysts project significant upside, with a 248% potential gain based on a $63.07 target, though risks persist due to the biotech sector's development uncertainties.